Olmesartan medoxomil [orch, phsu]
Angiotensin II Receptor Blocker [phsu]
Regulation [gora]
activity [dora]
Renin-Angiotensin-Aldosterone System [bdsy]
Management [ocac]
Cardiovascular disease [dsyn]
Olmesartan medoxomil [orch, phsu]
CS 866 [orch, phsu]
Angiotensin II Receptor Blocker [phsu]
Approved [qlco]
treatment [ftcn]
Hypertension [dsyn]
Objective [inpr]
Mechanism [ftcn]
Action [ftcn]
Pharmacokinetics [phsf]
Adverse Effect [fndg]
Profile [lbpr]
Drug interaction [moft]
Olmesartan medoxomil [orch, phsu]
Relevant [qlco]
Efficacy [qlco]
Safety [hcpp]
Trial [resa]
Methods [inpr]
Based [ftcn]
Published [ocac]
Efficacy [qlco]
Safety [hcpp]
Trial [resa]
Abstract [ocac]
Conference [hcpp]
presentations [idcn]
Appropriate [qlco]
English Language [lang]
Publications [inpr, mnob]
MEDLINE [inpr]
Searched [acty]
Term [tmco]
Olmesartan medoxomil [orch, phsu]
CS 866 [orch, phsu]
Angiotensin II Receptor Blocker [phsu]
Hypertension [dsyn]
Olmesartan medoxomil [orch, phsu]
Reported [inpr]
effective [qlco]
Agent [chvf]
treatment [ftcn]
Hypertension [dsyn]
Blood Pressure [orgf]
lowering [spco]
effects [qlco]
Anti-Hypertensive Agents [phsu]
effects [qlco]
Seen [qlco]
2 Weeks [tmco]
Olmesartan medoxomil [orch, phsu]
Administered [ftcn]
Maximum [qnco]
Recommended [idcn]
Daily Dose [qnco]
mg% [qnco]
Severe [qlco]
Renal insufficiency [dsyn]
Creatinine clearance [fndg]
mL/min [qnco]
Moderate [qlco]
Hepatic Insufficiency [patf]
Child-Pugh Score [inpr]
Daily Dose [qnco]
mg% [qnco]
Olmesartan medoxomil [orch, phsu]
Well [qlco]
Reported [inpr]
Adverse Effect [fndg]
Often [tmco]
Olmesartan medoxomil [orch, phsu]
placebo [topp]
Dizziness [sosy]
Seen [qlco]
Patients [podg]
occurrence [ftcn]
Drug Interactions [moft]
Minimal [qlco]
Conclusions [idcn]
Based [ftcn]
Available [ftcn]
Literature [inpr]
Olmesartan medoxomil [orch, phsu]
effective [qlco]
Angiotensin II Receptor Blocker [phsu]
treatment [ftcn]
Hypertension [dsyn]
Favorable [qlco]
Adverse Effect [fndg]
Drug interaction [moft]
Profile [lbpr]
Copyright [inpr]
